Gliperin (Glimepiride)

Gliperin is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic control.

• As monotherapy for patients with newly diagnosed type 2 diabetes.
• In combination with metformin when metformin alone does not achieve target glucose levels.
• As part of a fixed‑dose combination regimen with other oral antidiabetic agents.
• To improve fasting and post‑prandial blood glucose concentrations.
• For use in patients whose renal function permits sulfonylurea therapy.

Gliperin may cause a range of adverse effects, most of which are mild and transient, while rare events can be serious and require medical attention.

Common

• Mild hypoglycemia, especially when meals are skipped or delayed.
• Nausea or abdominal discomfort.
• Headache or dizziness.
• Weight gain due to increased insulin activity.
• Transient fatigue or weakness.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions such as rash, itching, or swelling.
• Hematologic abnormalities like leukopenia or thrombocytopenia.
• Hepatic dysfunction presenting as jaundice or elevated liver enzymes.
• Pancreatitis with abdominal pain and elevated enzymes.

Before initiating Gliperin therapy, healthcare providers should evaluate patient-specific factors and monitor for conditions that may increase the risk of adverse outcomes.

• Assess renal and hepatic function; dose adjustments may be needed in impairment.
• Review history of cardiovascular disease, as sulfonylureas can affect cardiac ischemia.
• Caution in elderly patients due to higher susceptibility to hypoglycemia.
• Avoid use during pregnancy and lactation unless benefits outweigh risks.
• Monitor blood glucose regularly to detect hypoglycemia early.
• Consider potential for weight gain and adjust lifestyle counseling accordingly.
• Screen for allergic reactions if the patient has known sulfonylurea sensitivity.

Gliperin can interact with several medicines, altering blood glucose levels or increasing the risk of side effects; awareness of these interactions helps ensure safe use.

Avoid

• Concurrent use with other sulfonylureas or insulin, which may cause severe hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that raise glimepiride concentrations.
• MAO‑B inhibitors, which can potentiate hypoglycemic effects.

Use with caution

• Beta‑blockers, as they may mask hypoglycemia symptoms.
• Thiazide diuretics, which can affect glucose tolerance.
• Oral contraceptives, potentially altering glimepiride metabolism.
• Antifungal agents like itraconazole, requiring closer glucose monitoring.